Ciluprevir
| Code | Size | Price |
|---|
| TAR-T19627-5mg | 5mg | £1,492.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T19627-50mg | 50mg | £2,946.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T19627-100mg | 100mg | £4,006.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Ciluprevir is an effective and selective HCV NS3 protease inhibitor with proven antiviral effect in humans. Ciluprevir may be an antiviral agent for individuals infected with non-genotype-1 HCV. In vitro sensitivity studies with Ciluprevir showed a decrease in affinity for proteases of genotypes 2 and 3 (Ki: 80 to 90 nM) compared to genotype 1 enzymes (Ki: 1.5 nM).
CAS:
300832-84-2
Formula:
C40H50N6O8S
Molecular Weight:
774.93
Purity:
0.98
SMILES:
[H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](CN1C(=O)[C@H](CCCCCC=C/2)NC(=O)OC1CCCC1)Oc1cc(nc2cc(OC)ccc12)-c1csc(NC(C)C)n1)C(O)=O
References
1. Busacca CA, Jones PJ, Campbell SJ, Saha AK, Gonnella NC, Senanayake CH. Probing the cation binding modes of macrocyclic HCV protease inhibitor BILN 2061 by multinuclear NMR. J Pharm Biomed Anal. 2012 Nov;70:609-13. doi: 10.1016/j.jpba.2012.06.013. Epub 2012 Jun 15. PubMed PMID: 22766359.
2. Stoltz JH, Stern JO, Huang Q, Seidler RW, Pack FD, Knight BL. A twenty-eight-day mechanistic time course study in the rhesus monkey with hepatitis C virus protease inhibitor BILN 2061. Toxicol Pathol. 2011 Apr;39(3):496-501. doi: 10.1177/0192623311398276. Epub 2011 Mar 25. PubMed PMID: 21441227.
3. Shu C, Zeng X, Hao MH, Wei X, Yee NK, Busacca CA, Han Z, Farina V, Senanayake CH. RCM macrocyclization made practical: an efficient synthesis of HCV protease inhibitor BILN 2061. Org Lett. 2008 Mar 20;10(6):1303-6. doi: 10.1021/ol800183x. Epub 2008 Feb 23. PubMed PMID: 18293994.
4. Vanwolleghem T, Meuleman P, Libbrecht L, Roskams T, De Vos R, Leroux-Roels G. Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse. Gastroenterology. 2007 Oct;133(4):1144-55. Epub 2007 Jul 10. PubMed PMID: 17919490.